MedPath
Found 4 clinical trials|View Analysis
Sort by:

Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care

Phase 2
Active, not recruiting
Conditions
Locally Advanced Malignant Neoplasm
Delirium
Recurrent Malignant Neoplasm
Metastatic Malignant Neoplasm
Interventions
Drug: Haloperidol
Drug: Lorazepam
Other: Placebo
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
First Posted Date
2018-11-16
Last Posted Date
2025-01-10
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
110
Registration Number
NCT03743649
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

🇺🇸

Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States

🇧🇷

Hosptial de Cancer de Barretos, Barretos, Sao Paulo, Brazil

Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation

Phase 4
Terminated
Conditions
Haloperidol Causing Adverse Effects in Therapeutic Use
Loxapine Causing Adverse Effects in Therapeutic Use
Agitation,Psychomotor
Lorazepam Causing Adverse Effects in Therapeutic Use
Interventions
First Posted Date
2017-04-12
Last Posted Date
2018-06-11
Lead Sponsor
University of Arkansas
Target Recruit Count
2
Registration Number
NCT03110900
Locations
🇺🇸

University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer

Phase 2
Active, not recruiting
Conditions
Advanced Cancers
Interventions
Drug: Placebo
Drug: Lorazepam
Drug: Haloperidol decanoate
Behavioral: Questionnaires
First Posted Date
2013-09-24
Last Posted Date
2024-07-29
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
93
Registration Number
NCT01949662
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Intramuscular (IM) Olanzapine Versus IM Haloperidol Plus Lorazepam for Acute Agitation in Schizophrenia

Phase 3
Completed
Conditions
Agitation
Schizoaffective Disorder
Schizophrenia
Interventions
First Posted Date
2008-11-25
Last Posted Date
2014-09-15
Lead Sponsor
National Taiwan University Hospital
Target Recruit Count
67
Registration Number
NCT00797277
Locations
🇨🇳

Department of Psychiatry, National Taiwan University Hospital, Taipei, Taiwan

© Copyright 2025. All Rights Reserved by MedPath